IL285282A - Antibodies that bind to Plasmodium circumsporozoite protein and their uses - Google Patents

Antibodies that bind to Plasmodium circumsporozoite protein and their uses

Info

Publication number
IL285282A
IL285282A IL285282A IL28528221A IL285282A IL 285282 A IL285282 A IL 285282A IL 285282 A IL285282 A IL 285282A IL 28528221 A IL28528221 A IL 28528221A IL 285282 A IL285282 A IL 285282A
Authority
IL
Israel
Prior art keywords
antibodies binding
circumsporozoite protein
plasmodium circumsporozoite
plasmodium
protein
Prior art date
Application number
IL285282A
Other languages
English (en)
Hebrew (he)
Original Assignee
Humabs Biomed Sa
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa, Vir Biotechnology Inc filed Critical Humabs Biomed Sa
Publication of IL285282A publication Critical patent/IL285282A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL285282A 2019-04-30 2021-08-01 Antibodies that bind to Plasmodium circumsporozoite protein and their uses IL285282A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/061135 WO2020221451A1 (en) 2019-04-30 2019-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof
PCT/EP2020/062167 WO2020221910A1 (en) 2019-04-30 2020-04-30 Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Publications (1)

Publication Number Publication Date
IL285282A true IL285282A (en) 2021-09-30

Family

ID=66429360

Family Applications (1)

Application Number Title Priority Date Filing Date
IL285282A IL285282A (en) 2019-04-30 2021-08-01 Antibodies that bind to Plasmodium circumsporozoite protein and their uses

Country Status (13)

Country Link
US (1) US20230084102A1 (cg-RX-API-DMAC7.html)
EP (1) EP3962513A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022531552A (cg-RX-API-DMAC7.html)
KR (1) KR20220004055A (cg-RX-API-DMAC7.html)
CN (1) CN114206921B (cg-RX-API-DMAC7.html)
AU (1) AU2020266283A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016341A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130805A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192930A1 (cg-RX-API-DMAC7.html)
IL (1) IL285282A (cg-RX-API-DMAC7.html)
MX (1) MX2021013252A (cg-RX-API-DMAC7.html)
SG (1) SG11202108585QA (cg-RX-API-DMAC7.html)
WO (2) WO2020221451A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021257665A1 (en) * 2020-06-19 2021-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody that targets a conserved site on the plasmodium falciparum circumsporozoite protein
US20240287166A1 (en) * 2021-05-28 2024-08-29 David Weiner Dna antibody constructs for use against plasmodium parasites
CN117467005A (zh) * 2023-11-15 2024-01-30 深圳重链生物科技有限公司 抗疟原虫单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
CN103611151A (zh) * 2013-12-06 2014-03-05 广东药学院 疟原虫环子孢子蛋白多肽CSP I-plus 在制备抗疟疾药物中的应用
EP3612562A2 (en) * 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to

Also Published As

Publication number Publication date
AU2020266283A1 (en) 2021-09-02
CN114206921B (zh) 2024-05-14
WO2020221451A1 (en) 2020-11-05
BR112021016341A2 (pt) 2021-10-26
SG11202108585QA (en) 2021-11-29
MX2021013252A (es) 2021-11-17
CN114206921A (zh) 2022-03-18
US20230084102A1 (en) 2023-03-16
JP2022531552A (ja) 2022-07-07
WO2020221910A1 (en) 2020-11-05
KR20220004055A (ko) 2022-01-11
EP3962513A1 (en) 2022-03-09
CA3130805A1 (en) 2020-11-05
EA202192930A1 (ru) 2022-02-24

Similar Documents

Publication Publication Date Title
SG11202010237RA (en) Fusion protein binding to cd47 protein and application thereof
IL287613A (en) Antibodies that bind gprc5d
IL273199A (en) GPCR binding proteins and their synthesis
ZA202003133B (en) Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof
IL274926A (en) Pyrazolopyrimidines with activity against respiratory syncytial virus
IL265489B (en) Recombinant binding proteins and their uses
IL261666A (en) Related proteins and methods of using them
ZA201905341B (en) Antibodies specifically binding to human il-1r7
ZA201902297B (en) Low-viscosity antigen binding proteins and methods of making them
IL286634A (en) Antibodies to intracellular amyloid pyroglutamate and uses thereof
HUE063272T2 (hu) Zika-vírus epitópokhoz specifikusan kötõdõ új antitestek és alkalmazásaik
IL272103A (en) Antigen-binding proteins binding to 5T4 and 4-1BB, compositions and methods
IL289145A (en) il1rap binding proteins
IL259519B (en) cd131 binding proteins and their uses
SG11201606018UA (en) Binding proteins and methods of use thereof
GB201802338D0 (en) Antigen binding proteins
GB201919294D0 (en) Antibodies or binding proteins
ZA201901862B (en) Modified factor h binding protein
HK40066563A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
SG11202001813UA (en) Polypeptide and antibody bound to polypeptide
ZA202001042B (en) Antibody specifically binding to pauf protein, and use thereof
HK40015287A (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
GB201919286D0 (en) Binding proteins
IL261033A (en) Human antibodies and tensin-binding fragments
GB201804531D0 (en) Antigen binding proteins